Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $40.72 | 52-week high | $71.71 |
| Prev. close | $40.61 | 52-week low | $7.79 |
| Day low | $40.51 | Volume | 802,300 |
| Day high | $42.38 | Avg. volume | 1,235,600 |
| 50-day MA | $53.32 | Dividend yield | N/A |
| 200-day MA | $47.93 | Market Cap | 2.14B |
JANX Stock Price Chart Interactive Chart >
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Price Returns
| 1-mo | -28.35% |
| 3-mo | -21.31% |
| 6-mo | -4.77% |
| 1-year | 321.53% |
| 3-year | 191.27% |
| 5-year | N/A |
| YTD | -23.94% |
| 2024 | 398.97% |
| 2023 | -18.53% |
| 2022 | -33.25% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...